Alcresta Therapeutics Expands RELiZORB Indication for Young Patients
Alcresta Therapeutics, Inc., known for its innovative enzyme-based products, has recently announced a significant milestone concerning its product RELiZORB. This digestive enzyme cartridge is now FDA-approved for use in pediatric patients aged one year and older. This clearance marks a pivotal advancement in nutritional care for infants and young children suffering from fat malabsorption.
Understanding RELiZORB and Its Functionality
RELiZORB is designed to act as a substitute for pancreatic lipase, an enzyme crucial for digesting fats. For children aged one and above, this device can substantially enhance their ability to absorb essential nutrients from enteral formulas, promoting healthier growth and development. The indication expansion was based on real-world data that demonstrated the effectiveness and safety of RELiZORB in younger populations.
Significance of the Expanded Indication
The allowance for children as young as one year old to utilize RELiZORB represents a considerable step forward in pediatric nutritional health. According to Dan Orlando, CEO of Alcresta Therapeutics, this approval is vital for enterally fed patients, especially those with conditions like short bowel syndrome (SBS). SBS patients often face significant challenges in nutrient absorption, making such advancements critical.
RELiZORB's Unique Technology
Alcresta developed RELiZORB using its proprietary immobilization technology, iLipase. The cartridge features pancreatic lipase bound to polymeric beads, allowing for efficient fat hydrolysis as the enteral formula passes through the device. As fat is broken down, it becomes more absorbable, directly addressing the nutritional needs of patients with pancreatic insufficiency and other gastrointestinal disorders.
Market Introduction and Previous Approvals
RELiZORB was first approved by the FDA in 2015 for adult patients. The subsequent expansion to pediatric patients began in 2017, initially allowing use in children aged five and older, then extending further to those aged two and above in 2023. The latest enhancement in 2024 solidifies its place in pediatric dietary care by broadening compatible formulas and improving user experience with multiple daily use options.
About Alcresta Therapeutics, Inc.
Dedicated to addressing the needs of patients suffering from gastrointestinal conditions, Alcresta Therapeutics is committed to releasing innovative products that enhance nutritional absorption and overall health. Their flagship product, RELiZORB, caters to enterally fed individuals experiencing pancreatic insufficiency due to various medical conditions. The company is also exploring applications for newborns in the neonatal intensive care unit (NICU), underscoring its focus on vulnerable populations.
Current Developments and Future Outlook
As Alcresta continues to develop its product range, it aims to better serve patients with rare diseases and complex nutritional needs. Through ongoing research and product innovation, the company is well-positioned to make significant contributions to pediatric care and beyond.
Frequently Asked Questions
What is RELiZORB?
RELiZORB is a digestive enzyme cartridge designed to assist in the breakdown of fats in enteral formulas, improving nutrient absorption for patients who cannot adequately digest fats on their own.
Who can use RELiZORB?
RELiZORB is approved for use in both pediatric patients aged one and older and adult patients needing enhanced nutritional support due to pancreatic insufficiency or fat malabsorption conditions.
Why was the indication for RELiZORB expanded?
The expansion was based on real-world clinical evaluations showing that younger patients aged one to two years experienced no additional safety issues while using RELiZORB with enteral formulas.
What does the approval mean for young patients?
This approval means that children who have trouble absorbing nutrients, especially fats, now have access to a crucial tool that can aid in their growth and nutritional intake.
What future applications is Alcresta developing?
Alcresta is working on applications for premature infants in NICUs, further broadening its impact in pediatric and specialized nutritional care.
